急性髓细胞白血病患者联合检测血清VEGF和sPD-L1对疗效及预后评估价值的研究  

Value of combined detection of serum levels of vascular endothelial growth factor and soluble programmed death factor ligand-1 in assessing the clinical efficacy and prognosis in patients with acute myeloid leukemia

作　　者：王改锋[1] 张琰[1] 王升[1] 杨卫东[1] 郭芳[1] 赵艳秋[1] Wang Gaifeng;Zhang Yan;Wang Sheng;Yang Weidong;Guo Fang;Zhao Yanqiu(Second Department of Hematology,Anyang District Hospital of Puyang City, Puyang, He’nan 455000, China)

机构地区：[1]濮阳市安阳地区医院血液二科

出　　处：《感染．炎症．修复》2019年第1期41-45,共5页Infection Inflammation Repair

摘　　要：目的:探讨血清血管内皮生长因子(VEGF)、可溶性程序性死亡因子配体-1(sPD-L1)联合检测在急性髓细胞白血病(AML)患者疗效、预后评估中的应用价值。方法:选择2014年6月—2017年8月收治的AML患者96例作为病例组,同期68例健康体检者为健康对照组。比较两组间及不同FAB分型AML患者间血清VEGF、sPD-L1水平。病例组均采取1个疗程诱导化疗,比较不同疗效患者血清VEGF、sPD-L1水平。治疗后随访6个月,依据患者临床结局将其分为死亡患者及存活患者,比较其血清VEGF、sPD-L1水平。结果:病例组血清VEGF、sPD-L1水平均高于健康对照组(P<0.05);病例组不同FAB分型患者血清VEGF、sPD-L1水平相比,差异无统计学意义(P>0.05);病例组不同疗效患者血清VEGF、sPD-L1水平相比,差异有显著性(P<0.05),完全缓解患者上述指标水平低于部分缓解及未缓解患者,部分缓解患者低于未缓解患者(P<0.05);病例组存活患者血清VEGF、sPD-L1水平低于死亡患者(P<0.05)。结论:急性髓细胞白血病患者血清VEGF、sPD-L1水平均呈高表达,且高水平的血清VEGF、sPD-L1预示患者治疗效果和临床结局较差,因此可将其作为AML疗效、预后评估的重要指标。Objective: To investigate the value of combined detection of serum levels of vascular endothelial growth factor (VEGF) and soluble programmed death factor ligand-1 (sPD-L1) in evaluating the efficacy and prognosis of patients with acute myeloid leukemia (AML). Methods: Ninety-six patients with AML admitted from June 2014 to Aug. 2017 were selected as the case group, and 68 healthy people as the healthy control group during the same period. Serum levels of VEGF and sPD-L1 were compared between the two groups and between AML patients with different FAB types. The patients in the case group received one course of induction chemotherapy, and the serum levels of VEGF and sPD-L1 were compared between the patients with different therapeutic effects. The patients were followed up for 6 months. According to the clinical outcomes, the patients were divided into dead patients and survivors, and their serum levels of VEGF and sPD-L1 were compared. Results: Serum levels of VEGF and sPD-L1 in case group were higher than those in healthy control group (P < 0.05). There was no a significant difference in serum levels of VEGF and sPD-L1 between patients with different FAB types (P > 0.05). There was significant difference in serum levels of VEGF and sPD-L1 between patients with different therapeutic effects (P < 0.05), and the above-mentioned indexes in patients with complete remission were lower than that in patients with partial remission or no remission(P < 0.05), and they were lower in patients with partial remission than that in patients without remission (P < 0.05). The two indexes in survivors were lower than those in dead patients (P < 0.05). Conclusions: Serum levels of VEGF and sPD-L1 in patients with AML are highly expressed, and the AML patients with higher serum levels of VEGF and sPD-L1 have poor therapeutic effect and clinical outcome, indicating that the serum levels of VEGF and sPD-L1 can be used as important indicators for evaluating the efficacy and prognosis of AML.

关 键 词：急性髓细胞白血病 血管内皮生长因子 可溶性程序性死亡因子配体-1 疗效评估 

分 类 号：R55[医药卫生—血液循环系统疾病]